(Reuters) – U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk’s highly in-demand drugs for diabetes and weight loss, according to a […]

CHICAGO — A preview of much-anticipated updates to guidelines on managing thyroid disease in pregnancy shows key changes to recommendations in the evolving field, ranging from […]

SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated with decreased alcohol use, new research suggests. The findings, from […]

CHICAGO — Endocrinologists may be shifting toward greater use of antithyroid drugs (ATDs) over radioactive iodine (RAI) for initial treatment of Graves’ disease. Severe thyrotoxicosis remains […]

The “dawn phenomenon” (DP) describes a pattern in which episodes of hyperglycemia are experienced by patients with diabetes or prediabetes during the early morning hours (usually […]

San Antonio — Despite the prevalence of obesity in primary care, there appear to be major knowledge gaps among providers regarding obesity management, new research suggests.  […]

LONDON (Reuters) -Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on […]

LONDON (Reuters) -Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and 100 hospitalisations of […]